KERX

Keryx Biopharmaceuticals, Inc. News Headlines

$13.91
*  
0.15
 negative 
1.07%
Get KERX Alerts
*Delayed - data as of Apr. 15, 2014 
Exchange: NASDAQ
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save stocks for next time
Viewing
Filtered By
Ordered By

Keryx Biopharmaceuticals Strengthens Leadership Team With Key Additions in Sales, Corporate Development and Legal
4/15/2014 8:30:00 AM - GlobeNewswire

Keryx Biopharmaceuticals Announces Zerenex(TM) (Ferric Citrate Coordination Complex) Phase 2 Results in Non-Dialysis Dependent Chronic Kidney Disease Selected as a Late Breaking Oral Presentation at the Upcoming National Kidney Foundation 2014 Spring Clin
4/9/2014 8:30:00 AM - GlobeNewswire

Health Care Sector Stocks under Review -- Research on Sanofi, Impax Laboratories, Keryx Biopharma, and Rigel Pharma
4/8/2014 1:59:00 PM - PR Newswire

Keryx Biopharmaceuticals Announces EMA Validation of Marketing Authorization Application for Zerenex(TM)
4/2/2014 8:30:00 AM - GlobeNewswire

Foresite Capital Closes $300 Million Fund II to Finance Late-Stage Healthcare Companies
4/1/2014 8:00:00 AM - Business Wire

Health Care Equities Analysis -- Research on Keryx Biopharma, Rigel Pharma, Sanofi and Impax Laboratories
3/19/2014 8:41:00 AM - PR Newswire

Healthcare Companies Report Financial Results, Partnerships, and Recognitions - Analyst Notes on Keryx, WellCare, Zogenix, Orexigen Therapeutics, and XOMA
3/19/2014 8:00:00 AM - PR Newswire

Keryx Biopharmaceuticals' Zerenex(TM) Data Selected for Poster Presentation at the AMCP's 26th Annual Meeting and Expo
3/17/2014 8:30:00 AM - GlobeNewswire

Keryx Biopharmaceuticals, Inc. Announces Fourth Quarter and Year-End 2013 Financial Results
3/12/2014 4:30:00 PM - GlobeNewswire

Keryx Biopharmaceuticals, Inc. to Host Conference Call on Fourth Quarter and Year End 2013 Financial Results
3/11/2014 4:30:00 PM - GlobeNewswire

Keryx Biopharmaceuticals Announces Submission of a Marketing Authorization Application for Zerenex(TM) to the European Medicines Agency
3/10/2014 8:30:00 AM - GlobeNewswire

Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences
2/26/2014 8:30:00 AM - GlobeNewswire

Keryx Biopharmaceuticals Announces the Appointment of Abraham Ceesay as Vice President of Marketing
2/18/2014 8:30:00 AM - GlobeNewswire

Keryx Biopharmaceuticals Appoints Greg Madison as Chief Operating Officer
2/10/2014 8:30:00 AM - GlobeNewswire

Keryx Biopharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference
2/6/2014 8:30:00 AM - GlobeNewswire

Keryx Biopharmaceuticals Announces Pricing of Public Offering of Common Stock
1/22/2014 7:42:00 PM - PR Newswire

Keryx Biopharmaceuticals, Inc. Announces $90 Million Proposed Public Offering of Common Stock
1/21/2014 4:19:00 PM - PR Newswire

Keryx Biopharmaceuticals Announces Appointment of Daniel W. Olmstead as Vice President, Payer Access
1/21/2014 8:30:00 AM - GlobeNewswire

Keryx Biopharmaceuticals Announces Marketing Approval of Ferric Citrate in Japan
1/17/2014 8:00:00 AM - PR Newswire